Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of TBI-1501 (CD19 CAR-T) for Relapsed or Refractory CD19-positive B-acute Lymphoblastic Leukemia
jRCT1080223510Phase 2Completed
- Sponsor
- Takara Bio Inc.
- Start
- Apr 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NIB-101 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Takara Bio Inc. Started Apr 2017; status: completed.
02
Drugs
NIB-101
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on jRCT1080223510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223510.